KBI Biopharma vs Northway Biotech: CDMO Comparison

How does KBI Biopharma compare to Northway Biotech?

As of Nov 2026, KBI Biopharma: 2 FDA inspections (including 0 NAI, 2 VAI and 0 OAI), 1 EMA/MHRA GMP certificate. Signal Score 84.1. Northway Biotech: no FDA inspections on file, 8 EMA/MHRA GMP certificates. Signal Score 80.8. Counts are the established FDA, EMA and MHRA records on each profile. CDMOs cannot pay to change a score.

Side-by-side comparison of KBI Biopharma and Northway Biotech on independent FDA inspections, EMA and MHRA GMP certificates, clinical-program activity, and CDMO Signal Score. Data sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.

Durham, NC · Boulder, CO
Signal Score
84/100
Quality (FDA + GMP)
98/100
FDA inspections
2
— NAI / VAI / OAI
0 / 2 / 0
FDA warning letters
0
EMA GMP certificates (active)
0
MHRA GMP certificates (compliant)
1
Clinical programs (matched)
0
Capacity
Limited
Modalities
Monoclonal Antibody, Recombinant Protein, AAV (analytical only), Plasmid DNA
Vilnius, LT; Waltham (MA), USA
Signal Score
81/100
Quality (FDA + GMP)
100/100
FDA inspections
0
FDA warning letters
0
EMA GMP certificates (active)
8
MHRA GMP certificates (compliant)
0
Clinical programs (matched)
0
Capacity
Available
Modalities
Biologics, mAbs, Recombinant proteins, pDNA, AAV, Viral vectors, Gene Therapy

Key differences

  • KBI Biopharma has FDA inspections on record (2); Northway Biotech does not yet appear in the FDA inspection database.
  • Both maintain clean enforcement records — no FDA OAI classifications or warning letters on file for either CDMO.
  • Northway Biotech holds 8 active EMA GMP certificates; KBI Biopharma does not appear in EudraGMDP.
  • KBI Biopharma maintains 1 MHRA / UK GMP certificate; Northway Biotech does not.

Across the cross-modality scorecard, KBI Biopharma carries the higher composite Signal Score — but the right choice depends on the specific modality, phase, and geography of the program.

Frequently asked: KBI Biopharma vs Northway Biotech

How does KBI Biopharma compare to Northway Biotech?

On CDMO Signal's composite Signal Score, KBI Biopharma is 84/100 and Northway Biotech is 81/100; KBI Biopharma has 2 FDA inspections on record vs 0 for Northway Biotech; European coverage is 1 active EMA+MHRA certificate for KBI Biopharma vs 8 for Northway Biotech. Both are tracked in the CDMO Signal directory. The scorecard above breaks down every metric side by side — use it alongside each CDMO's individual profile for the full regulatory and clinical footprint.

Which has the stronger FDA inspection record, KBI Biopharma or Northway Biotech?

Both KBI Biopharma and Northway Biotech maintain clean enforcement records on file — no FDA warning letters and no OAI classifications. KBI Biopharma has 2 FDA inspections on record; Northway Biotech has 0.

How do KBI Biopharma and Northway Biotech compare on European GMP coverage?

KBI Biopharma holds 0 active EMA GMP certificates and 1 MHRA / UK certificate. Northway Biotech holds 8 active EMA GMP certificates and 0 MHRA / UK certificates. Use these counts as a proxy for the breadth of each CDMO's European regulatory footprint.

What does the Signal Score gap mean in practice?

KBI Biopharma carries a Signal Score of 84/100 and Northway Biotech carries 81/100 — essentially tied for KBI Biopharma. The Signal Score combines quality (FDA inspections + EMA/MHRA GMP), operational performance, financial stability, and capacity intelligence. CDMOs cannot pay to influence their score.

Evaluating KBI Biopharma and Northway Biotech for a program?

Use the free AI matchmaker to weigh both against your specific requirements — capacity, modality, regulatory record, geography — and surface other qualified options.

Find & compare CDMOs →
Sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.